Cooper Companies (The) (COO) Stock Price, Fundamentals & Analysis

What COO does

Cooper Companies (The) (COO) is a US healthcare stock listed on the US market, headquartered in San Ramon, United States, with around 15,000 employees. Founded in 1958, the company develops, manufactures, and markets contact lenses and related products. It operates through two segments: CooperVision, which offers spherical, toric, and multifocal contact lenses addressing vision challenges such as astigmatism, presbyopia, and myopia, and CooperSurgical, which focuses on family and women's health care — including fertility products and services, medical devices, contraception (notably Paragard, a hormone-free intrauterine device), and cryostorage such as cord blood and cord tissue storage. Its customers include distributors, group purchasing organizations, eye care and health care professionals, hospitals and clinics, and authorized resellers. It sits in the Medical Instruments & Supplies industry, a space that also includes peers like Thermo Fisher Scientific (TMO), GE HealthCare (GEHC), and Mettler Toledo (MTD).

Key numbers explained

For a beginner, here is how the main figures are typically read:

• Price: 56.07 USD, up +1.41% today. Over the last 52 weeks the stock traded between 51.01 and 89.83 USD and is down -19.1% from a year ago.
• Market capitalization — the total value of all shares — is 10.66B USD, which places COO among mid-sized healthcare companies.
• The trailing P/E ratio of 19.3 means the share price costs about 19 times the company's earnings per share over the past 12 months (2.91 USD per share). The forward P/E of 11.9 is based on expected earnings instead.
• The dividend yield is 0% — the company currently pays no dividend, and 0% of earnings are paid out as dividends. The last ex-dividend date was Jul 26, 2023.
• Profit margin is 13.5% and operating margin is 20.8%, showing how much of each revenue dollar remains after costs; trailing 12-month revenue is 4.24B USD, growing just 0.6% year over year.
• Return on equity of 6.8% indicates how efficiently shareholder capital generates profit.
• A beta of 0.82 suggests the stock has historically moved somewhat less than the overall market.
• A debt-to-equity ratio of 33.6% and a price-to-book ratio of 1.28 round out the balance-sheet and valuation picture.

Recent news

Recent headlines highlight CooperVision's push into the next era of eye care, with a new Global Vision Centre and major pipeline advancements, plus an accelerated CooperVision innovation strategy unveiled at The Vision Centre opening. Separately, an activist investor has urged Cooper Companies to replace its CEO and sell some assets, and the stock appeared in a piece titled "3 Out-of-Favor Stocks with Open Questions."

What to watch

As a medical devices and supplies company, COO's results tend to depend on demand for contact lenses and women's health products, innovation pipelines, and healthcare spending trends. The next earnings date is Sep 9, 2026, when updated results will be released. Investors commonly follow revenue growth (currently modest at 0.6%), margin trends, and any corporate governance developments. Comparisons with sector peers such as Elevance Health (ELV), Cigna (CI), ResMed (RMD), or Insulet Corporation (PODD) can provide context, and the stocks directory lists other companies in the space.